{"id":"biological-experimental-tezepelumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TSLP is an epithelial-derived cytokine that activates dendritic cells and promotes T helper 2 (Th2) cell differentiation, driving type 2 inflammatory responses. By neutralizing TSLP, tezepelumab suppresses the cascade of type 2 cytokines (IL-4, IL-5, IL-13) and reduces eosinophil activation, mast cell degranulation, and IgE production. This upstream mechanism addresses multiple type 2 inflammatory diseases including asthma and atopic dermatitis.","oneSentence":"Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine in type 2 inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:26.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe asthma (type 2 inflammation)"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT04048343","phase":"PHASE3","title":"Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-06-10","conditions":"Severe Asthma","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tezepelumab"],"phase":"phase_3","status":"active","brandName":"Biological: Experimental: Tezepelumab","genericName":"Biological: Experimental: Tezepelumab","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine in type 2 inflammation. Used for Moderate-to-severe asthma (type 2 inflammation), Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}